Placebo for IMU-838 Tablets
Sponsors
Immunic AG
Conditions
Progressive forms of Multiple SclerosisRelapsing Multiple SclerosisRelapsing-remitting multiple sclerosis
Phase 2
P2-IMU-838-MS - Randomized, double-blind, placebo-controlled, multicenter Phase 2 trial assessing the effect of IMU-838 on disease activity, as measured by magnetic resonance imaging (MRI), as well as safety and tolerability in patients with relapsingremitting multiple sclerosis (RRMS) (EMPhASIS)
RecruitingCTIS2024-516739-29-00
Start: 2019-01-23Target: 142Updated: 2025-04-03
P2-IMU-838-PMS - Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients with Progressive Multiple Sclerosis (Calliper)
RecruitingCTIS2024-514617-35-00
Start: 2021-12-20Target: 230Updated: 2025-04-03
Phase 3
P3-IMU-838-RMS-02 - A Multi-Center, Randomized, Double-Blinded Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 versus Placebo in Adults with Relapsing Multiple Sclerosis (ENSURE-2)
Active, not recruitingCTIS2024-514619-88-00
Start: 2022-03-18Target: 321Updated: 2025-04-03
P3-IMU-838-RMS-01 - A Multi-Center, Randomized, Double-Blinded Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 versus Placebo in Adults with Relapsing Multiple Sclerosis (ENSURE-1)
Active, not recruitingCTIS2024-514618-11-00
Start: 2022-03-01Target: 423Updated: 2025-04-03